Featured Research

from universities, journals, and other organizations

Robot may accelerate trials for stroke medications

Date:
February 11, 2014
Source:
Massachusetts Institute of Technology
Summary:
A new study's authors found that by using a robot's measurements to gauge patient performance, companies might only have to test 240 patients to determine whether a drug works -- a reduction of 70 percent that would translate to a similar reduction in time and cost.

After suffering a stroke, a patient learns to operate the robot MIT-Manus to improve mobility.
Credit: Photo courtesy of the researchers

The development of drugs to treat acute stroke or aid in stroke recovery is a multibillion-dollar endeavor that only rarely pays off in the form of government-approved pharmaceuticals. Drug companies spend years testing safety and dosage in the clinic, only to find in Phase III clinical efficacy trials that target compounds have little to no benefit. The lengthy process is inefficient, costly, and discouraging, says Hermano Igo Krebs, a principal research scientist in MIT's Department of Mechanical Engineering.

"Most drug studies failed and some companies are getting discouraged," Krebs says. "Many have recently abandoned the neuro area [because] they have spent so much money on developing drugs that don't work. They end up focusing somewhere else."

Now a robot developed by Krebs and his colleagues may help speed up drug development, letting pharmaceutical companies know much earlier in the process whether a drug will ultimately work in stroke patients.

To receive approval from the Food and Drug Administration, a company typically has to enroll 800 patients to demonstrate that a drug is effective during a Phase III clinical trial; this sample size is determined, in part, by the accuracy of standard outcome measurements, which quantify a patient's ability over time to, say, lift her arm past a certain point. A clinical trial can take several years to enroll appropriate patients, run tests, and perform analyses.

The study's authors found that by using a robot's measurements to gauge patient performance, companies might only have to test 240 patients to determine whether a drug works -- a reduction of 70 percent that Krebs says would translate to a similar reduction in time and cost.

While pharmaceutical companies would still have to adhere to the FDA's established guidelines and outcome measurements to receive final drug approval, Krebs says they could use the robot measurements to guide early decisions on whether to further pursue or abandon a certain drug. If, after 240 patients, a drug has no measurable effect, the company can pursue other therapeutic avenues. If, however, a drug improves performance in 240 robot-measured patients, the pharmaceutical company can continue investing in the trial with confidence that the drug will ultimately pass muster.

The researchers, including senior author Bruce Volpe of the Feinstein Institute for Medical Research in Manhasset, N.Y., and Michael Krams, of Janssen Research Development in Titusville, N.J., have published their results in the journal Stroke.

Creating a translator for stroke recovery

In their study, Krebs and his colleagues explored the robot MIT-Manus as a tool for evaluating patient improvement over time. The robot, developed by the team at MIT's Newman Laboratory for Biomechanics and Human Rehabilitation, has mainly been used as a rehabilitation tool: Patients play a video game by maneuvering the robot's arm, with the robot assisting as needed.

While the robot has mainly been used as a form of physical therapy, Krebs says it can also be employed as a measurement tool. As a patient moves the robot's arm, the robot collects motion data, including the patient's arm speed, movement smoothness, and aim. For the current study, the researchers collected such data from 208 patients who worked with the robot seven days after suffering a stroke, and continued to do so for three months.

The researchers created an artificial neural network map that relates a patient's motion data to a score that correlates with a standard clinical outcome measurement.

The authors then selected a separate group of nearly 3,000 stroke patients who did not use the robot, but who went through standard clinical tests. In particular, the researchers calculated the "effect size" -- the difference in patient performance from the beginning to the end of a trial, divided by the standard deviation, or variability, of improvement among these patients. To determine whether a drug works, the FDA will often look to a study's effect size.

Using the robot-derived neural network map, the group calculated the effect size at twice the rate usually achieved with standard clinical outcome measurements, indicating that the robot scale demonstrated greater sensitivity in measuring patient recovery.

The study's authors went one step further and performed a power analysis that determines the optimal sample size for a given technique, finding that the robot scale would require only 240 patients to determine a drug's effectiveness -- a reduction in sample size that would save a company up to 70 percent in time and cost.

"Such a savings would be fantastic," says David Reinkensmeyer, a professor of physical medicine and rehabilitation at the University of California at Irvine. "Robotic measurements will help us identify promising treatments with smaller numbers of patients and provide better insight into the mechanisms of the treatments, so that we can target those mechanisms and improve the treatments."

Currently, only a few stroke drugs are in the late stages of development. However, once a company reaches a Phase III clinical trial, Krebs says it may use the MIT-Manus robot as a more efficient way to evaluate the drug's impact by employing the measurement techniques on a smaller group of patients.


Story Source:

The above story is based on materials provided by Massachusetts Institute of Technology. The original article was written by Jennifer Chu. Note: Materials may be edited for content and length.


Journal Reference:

  1. H. I. Krebs, M. Krams, D. K. Agrafiotis, A. DiBernardo, J. C. Chavez, G. S. Littman, E. Yang, G. Byttebier, L. Dipietro, A. Rykman, K. McArthur, K. Hajjar, K. R. Lees, B. T. Volpe. Robotic Measurement of Arm Movements After Stroke Establishes Biomarkers of Motor Recovery. Stroke, 2013; 45 (1): 200 DOI: 10.1161/STROKEAHA.113.002296

Cite This Page:

Massachusetts Institute of Technology. "Robot may accelerate trials for stroke medications." ScienceDaily. ScienceDaily, 11 February 2014. <www.sciencedaily.com/releases/2014/02/140211113833.htm>.
Massachusetts Institute of Technology. (2014, February 11). Robot may accelerate trials for stroke medications. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2014/02/140211113833.htm
Massachusetts Institute of Technology. "Robot may accelerate trials for stroke medications." ScienceDaily. www.sciencedaily.com/releases/2014/02/140211113833.htm (accessed July 24, 2014).

Share This




More Matter & Energy News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Robot Parking Valet Creates Stress-Free Travel

Robot Parking Valet Creates Stress-Free Travel

AP (July 23, 2014) 'Ray' the robotic parking valet at Dusseldorf Airport in Germany lets travelers to avoid the hassle of finding a parking spot before heading to the check-in desk. (July 23) Video provided by AP
Powered by NewsLook.com
Boeing Ups Outlook on 52% Profit Jump

Boeing Ups Outlook on 52% Profit Jump

Reuters - Business Video Online (July 23, 2014) Commercial aircraft deliveries rose seven percent at Boeing, prompting the aerospace company to boost full-year profit guidance- though quarterly revenues missed analyst estimates. Bobbi Rebell reports. Video provided by Reuters
Powered by NewsLook.com
Europe's Car Market on the Rebound?

Europe's Car Market on the Rebound?

Reuters - Business Video Online (July 23, 2014) Daimler kicks off a round of second-quarter earnings results from Europe's top carmakers with a healthy set of numbers - prompting hopes that stronger sales in Europe will counter weakness in emerging markets. Hayley Platt reports. Video provided by Reuters
Powered by NewsLook.com
9/11 Commission Members Warn of Terror "fatigue" Among American Public

9/11 Commission Members Warn of Terror "fatigue" Among American Public

Reuters - US Online Video (July 22, 2014) Ten years after releasing its initial report, members of the 9/11 Commission warn of the "waning sense of urgency" in combating terrorists attacks. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins